Blocking stress protein relieves chronic pain
A group of drugs being developed to treat mood disorders could also relieve chronic pain, finds new UCL (University College London) research funded by the Medical Research Council.
A group of drugs being developed to treat mood disorders could also relieve chronic pain, finds new UCL (University College London) research funded by the Medical Research Council.
Nine weekly sessions of individually tailored acupuncture lessen perceived pain intensity, and improve functional capacity and quality of life, in people with the chronic pain condition, fibromyalgia, finds… read more.
by Bruce Sylvester: Researchers report that mindfulness meditation can significantly reduce pain but that it does not employ the endogenous opioid system to do so. The findings appeared… read more.
by Bruce Sylvester: Benzodiazepine therapy in older adults is not associated with an increase in dementia risk, researchers reported on Feb. 2, 2016 in The BMJ today.
by Bruce Sylvester: Researchers report that patients treated with the dementia drug rivastigimine are less likely to fall and are much steadier when walking, compared to patients receiving… read more.
by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.
by Gary Finnegan: The European Medicines Agency has set up a task force on Zika virus in an effort to accelerate the development of new medicines and vaccines… read more.
by Thomas R. Collins: Standing at the center of a decade and a half of stunning advancements in the treatment of multiple myeloma is the ubiquitin proteasome pathway… read more.
Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.
ASH 2015 proved to be all that we’d hoped for! We’ve witnessed unprecedented change in multiple myeloma with CR and VGPR percentages higher than ever… and most of this… read more.
by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.
by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.